Bringing the fundamentals into focus…
Back to Lakefront Biotherapeutics NV
How Lakefront Biotherapeutics NV stacks up
LKFT · against 396 other Healthcare companies of similar size
Profitability
93/ 100
Near the top of its peers.
Ranked #30 of 397 · scores higher than 92% of peers
Bars: peers in each 10-point band of the profitability score45 peers with a profitability score of 90–100, including LKFT · Click a bar to see the companies
Why profitability scores 93?
Weighted metrics compared with all Healthcare companies.Mainly thanks to its operating margin and return on assets, which are stronger than most Healthcare peers.
- Return on invested capital is not reported, so it is left out of the score.
- a higher return on assets: stronger than 90% of peers. Return on assets: 9.9% vs peer median 1.7%
- a wider operating margin: stronger than 98% of peers. Operating margin: 45.1% vs peer median 7.1%
Metric by metric
Position: dot = LKFT, ranked from the worst peer (left) to the best (right); tick = middle, shaded = middle half of peers.| Metric | LKFT | Peer median | Better than | Position among peers | Weight |
|---|---|---|---|---|---|
| Return on invested capitalHigher is better · 374 reported | Not reported | 5.9% | — | — | 33% |
| Operating marginHigher is better · 367 reported | 45.1% | 8.0% | 98% | 33% | |
| Return on assetsHigher is better · 380 reported | 9.9% | 2.0% | 91% | 33% | |
| Return on equityHigher is better · 366 reported | 20.1% | 4.8% | 90% | Context only | |
| Gross marginHigher is better · 411 reported | 67.6% | 48.9% | 73% | Context only |
A metric that is not reported is left out of the score; the other weights are rescaled.
Ranking by profitability score
Top 5 and the companies ranked around LKFT| Rank | Company | Market cap | Profitability | Overall |
|---|---|---|---|---|
| 1 | 3.1B EUR (≈$3.4B) | 100 | 100 | |
| 1 | 321.5B INR (≈$3.9B) | 100 | 70 | |
| 1 | 174.8B INR (≈$2.1B) | 100 | 73 | |
| 1 | 97.3B INR (≈$1.2B) | 100 | 80 | |
| 5 | 12.3B CNY (≈$1.7B) | 99 | 85 | |
| 25 | 2.6B USD | 94 | 66 | |
| 25 | 2.3B USD | 94 | 67 | |
| 30 | 11.3B CNY (≈$1.6B) | 93 | 76 | |
| 30 | 1.5B USD | 93 | 93 | |
| 30 | 2.1B USD | 93 | 96 | |
| 30 | 249.2B INR (≈$3.0B) | 93 | 73 | |
| 34 | 18.0B CNY (≈$2.5B) | 92 | 80 | |
| 34 | 13.3B CNY (≈$1.9B) | 92 | 73 | |
| 34 | 15.0B CNY (≈$2.1B) | 92 | 55 |
Scores are sector-relative percentiles from the latest snapshot, always calculated against the whole sector: narrowing the comparison group changes who you compare with, not the scores. Missing metrics are left out and the remaining weights rescaled. How we score